CASTLE BIOSCIENCES INC

Insightful insider sale analysis of Castle Biosciences (CBIO): why a COO’s 8,587‑share sell‑off matters for investors, clinical prospects, and future FDA approval.

Castle Biosciences’ CEO’s recent Rule 10(b)(5)(1) insider trades show disciplined buying at $2.39 and selling at $20.66, reflecting confidence in AI‑diagnostics growth and prudent capital management for investors.

Castle Biosciences insider buying: CEO Derek Maetzold’s Rule 10(b)(5)(1) purchase signals confidence, not distress—focus on pipeline progress, reimbursement, and scaling.